University of Thessaly (UTH)
Διερεύνηση του ρόλου των Cranberries (Vaccinium macrocarpon) στη μικροβιακή χλωρίδα της γυναίκας
Abstract
dc:descriptionBackground: Τhe adherence of p-fimbriated Escherichia coli (E. coli) to urothelial cells leading to recurrent urinary tract infections (rUTIs) may be prevented by proanthocyanidins (PACs) contained in American cranberries. Purpose: The purpose of this clinical trial was to assess the clinical utility of prophylactic use of high-dose PACs daily in women with a history of rUTIs. Materials and methods: Adult women aged with a history of rUTIs, defined as ≥2 within a 6-month period or ≥3 within a 12- month period were enrolled and randomized in two groups to receive either Cysticlean containing 240mg twice daily for 15 days followed by a maintenance dose of 240mg daily afterwards in the treatment arm, or placebo in the control arm for a 12-months period. At initial and quarterly study visits, urine samples, vaginal and rectal swabs were collected for detection of E. coli strains. The primary study endpoints were the number of urinary tract infections (UTIs) and changes in Quality of Life (QoL), assessed by the 36-Item Short Form Survey (SF-36) questionnaire. Secondary outcome measures were the number of women experiencing at least three UTIs, the UTI-free survival period, the number of positive E. coli colony- forming unit (cfu) in vaginal and rectal swabs, the asymptomatic bacteriuria events, and any adverse events. Results: 172 adult women of median age 40 years old (range 19-82) were enrolled in this randomized, placebo-controlled, double-blinded clinical trial. 160 subjects were analyzed, after excluding 12 patients due to poor compliance with treatment or/and follow-up visits. The primary objective of the study was reached as the number of UTIs was significantly lower in the intervention arm compared to placebo (Incidence rate ratio IRR 0.49, p<0.001). In addition, QoL assessed with SF-36 health change score was found slightly improved in patients treated with PACs. The numbers of E. coli isolates detected in vaginal (IRR 0.71, p-value<0.001) and in rectal swabs (IRR 0.87, p-value<0.001), respectively were also significantly decreased. No adverse events were reported. Conclusion: The use of 240mg PACs (CysticleanTM) daily was associated with a reduction of UTIs and an improvement in QoL compared to placebo treatment during a 12-month period in women with a history of rUTIs, supporting its use as prophylaxis in this patient population. Trial registration: Clinicaltrials.gov, identifier NCT03032003
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsiakoulias, Eleftherios
- Τσιακούλιας, Ελευθέριος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54903